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ABSTRACT 
Oncostatin M (OSM) is an interleukin-6 (IL-6) family cytokine shown to be 
important in inflammation, hematopoiesis, development, and bone homeostasis. Despite 
its role as a growth suppressor for many cancers, including breast cancer, OSM is 
currently being studied for its ability to promote tumor invasion and metastasis. 
Cathepsin D (CTSD) is a lysosomal protease found to be overexpressed and 
hypersecreted in breast and other cancers. In this study, we found OSM to induce the 
expression of CTSD protein in human breast cancer cells via the STAT3 and JNK2 
pathways. Next, we investigated mechanisms resulting in the increased secretion of 
CTSD from tumor cells. Previous reports have shown that acidic extracellular pH and 
cellular transformation stimulate lysosomal trafficking, increase secretion of lysosomal 
proteases, and increase invasion. In this study, we observed that OSM induced a change 
in cellular morphology and that CTSD-containing lysosomes traffic to the newly formed 
cellular protrusions. The trafficking and secretion of CTSD was dependent on Na+/H+ 
exchanger (NHE) activity and OSM activation of the PI3K and p38 MAPK pathways. 
OSM induced the secretion of physiologically active CTSD, which correlated with 
lysosomal location. Knockdown of CTSD also prevented an increase in invasive 
potential, even in the presence of OSM. Together, these results suggest that the 
expression of CTSD and location of CTSD-containing lysosomes are important aspects 
of the increase in invasive potential of tumor cells induced by OSM. This study provides 
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further evidence that OSM may be an important therapeutic target for in the early stages 
of breast cancer metastasis.  
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INTRODUCTION 
Over 200,000 new cases of breast cancer are reported each year in the United 
States. Moreover, breast cancer is the most commonly diagnosed cancer among women 
worldwide. The five-year survival rate of patients who present with distant metastases at 
the time of diagnosis is less than 25% 1, and breast cancer most commonly metastasizes 
to distant organs such as bone, liver, lung, and brain 2. Metastasis is a complex, multi-step 
process involving primary tumor cell invasion, intravasation, survival in the circulation, 
extravasation, and colonization of a secondary organ 3. In primary tumor cell invasion, 
proteases that are tightly controlled during mammary gland development and remodeling 
become deregulated and lead to excess extracellular matrix (ECM) degradation 4,5. In 
addition, the ECM is remodeled via processes normally involved in inflammation and 
wound-healing 6. This remodeling allows immune cells to infiltrate and provide 
additional ECM degrading proteases. The infiltrating immune cells also produce 
inflammatory cytokines that promote tumor progression such as those in the interleukin-6 
(IL-6) family that have been related to increased malignancy in several cancer types 7–12.   
The pleiotropic IL-6 family cytokine oncostatin M (OSM) has been shown to be 
important in inflammation, hematopoiesis, liver development and regeneration, 
neurogenesis, and bone homeostasis 13,14. OSM was originally found to act as an anti-
proliferative factor for A375 melanoma and other tumor cells in vitro 15, including 
multiple myeloma, lung cancer, glioblastoma, and breast cancer 16–18. In contrast, OSM 
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has been shown to increase proliferation in prostate and ovarian cancer cells 19,20. Despite 
its anti-proliferative effect, in vivo breast cancer research suggests a role for OSM in 
metastasis 8,21,22. We and others have shown that in vitro OSM 1) suppresses estrogen 
receptor expression implying the progression to a more aggressive phenotype 23, 2) 
enhances the transition of cancer cells from an epithelial to mesenchymal phenotype 
(EMT), which has been linked to the acquisition of tumor stem cell-like properties 22,24,25, 
and 3) increases detachment, invasion, and migration 21,26–29 via the upregulation of 
proteases that degrade the extracellular matrix (ECM) 7,27,30–33 and induction of 
proangiogenic factors, such as vascular endothelial growth factor (VEGF) 7,33–35, which 
are all important in the initial stages of metastasis.   
OSM and IL-6-family cytokines are known to activate several signal transduction 
pathways, including JAK/STAT3, PI3K/AKT, ERK1/2, JNK, and p38 MAPK 36–39, 
which have all been shown to play a role in breast cancer oncogenesis 40–43. OSM 
activates these pathways via its binding and heterodimerization of gp130 with either 
OSMR or LIFR 36–39,44. In ductal carcinoma in situ and invasive breast carcinoma, 
OSM8,45 (our unpublished results) and OSMR8 are expressed at higher levels than normal 
mammary epithelial cells, which express both at low levels. OSM can also be produced 
by both tumor-associated macrophages and neutrophils in response to cancer cells in vitro 
46–48
, suggesting autocrine and paracrine signaling by OSM in early stages of the 
metastatic cascade. How the OSM signaling pathway influences regulation of gene 
expression, angiogenesis, proteinase secretion, and cell motility and invasion are major 
areas of ongoing research. 
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Tumor cell invasion through the basement membrane and into the ECM involves 
local proteolysis and migration of tumor cells. Local proteolysis is facilitated by cell 
membrane bound and/or secreted proteases. Lysosomal proteases normally regulate many 
biological processes, such as tissue homeostasis, remodeling, and renewal by degrading 
and activating proteins within the lysosomes 49–51. Alterations in the expression, 
activities, processing, and localization of lysosomal enzymes have been observed in 
several cancer types52. Therefore, many studies have looked at the role of lysosomal 
enzymes in ECM proteolysis, mainly the cysteine proteases cathepsins B and L and 
aspartic acid protease cathepsin D. All have been shown to degrade components of the 
ECM either intracellularly within phagolysosomes 53,54 or extracellularly due to altered 
localization to the plasma membrane 55,56. Research also shows that anterograde 
trafficking of lysosomes (lysosomal movement away from the peri-nuclear region to the 
cell periphery) in malignant cells results in the secretion and exocytosis of  lysosomal 
proteases 57–61. These enzymes are synthesized as pro-enzymes and require activation at 
acidic pH found within endolysosomal vesicles 62–64. However, extracellular pro-
enzymes, such as cathepsin D (CTSD), can also undergo autoactivation 64,65 within the 
acidic extracellular environment hypothesized to occur in the tumor microenvironment 66. 
In addition, active CTSD can be secreted from necrotic cells 67. Once activated, CTSD 
can activate cathepsin B 68, promoting a cancer-associated proteolytic cascade further 
enhancing ECM degradation 69–72. 
Previously, we have shown the OSM increases the secretion of the cathepsins D 
and L in T47D breast cancer cells 27. In human breast cancer, increased CTSD expression 
is associated with a poor prognosis, worse overall survival, and poor relapse-free survival 
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73,74
. Higher expression levels of CTSD have been seen in node positive versus node 
negative breast cancer tissue. In addition, higher CTSD levels are seen in cells involved 
in metastatic reoccurrence75,76, while CTSD expression in the tumor stroma is associated 
with more aggressive breast cancer and an increase in microvessel density 77. In vitro, 
CTSD is upregulated by estrogen, epidermal growth factor, insulin-like growth factor I, 
and basic fibroblast growth factor in human estrogen responsive breast cancer cells 78–80. 
In human estrogen-independent breast cancer cell lines, CTSD was shown to be 
constitutively overexpressed 79,81, but recent reports show that thrombin 82 and the 
transcription factor c-myb 83 upregulate CTSD expression in these cell lines. Decreasing 
the expression, activity, and/or secretion of CTSD leads to a decrease in invasion and 
migration in human breast cancer and glioma cell lines 61,82–85, showing its importance in 
tumor cell metastasis.  
In this study, we show that OSM has a double influence on CTSD in human 
breast cancer cells. OSM both increases the expression of CTSD via STAT3 and JNK2 
activation and induces secretion of CTSD by promoting trafficking of lysosomes to the 
cell periphery in a manner dependent on PI3K, p38 MAPK, and NHE activity. In 
addition, we show that CTSD plays a role in the increased invasion seen by OSM-treated 
cancer cells. Overall, these findings indicate roles for lysosomal trafficking and 
lysosomal cathepsin D are key events in OSM-induced invasion of breast cancer cells.  
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MATERIALS AND METHODS 
Cell Culture and Cytokine Stimulation  
MCF7 and T47D human breast cancer cells are luminal epithelial-like estrogen 
receptor positive cells86. MCF7 and T47D cells were obtained directly from the American 
Type Culture Collection (Rockville, MD), maintained in RPMI-1640 media 
supplemented with 10% fetal bovine serum (FBS) and 100 U/mL each of penicillin and 
streptomycin. Cells were maintained at 37°C, 5% carbon dioxide, and 95% humidity. All 
media and supplements were obtained from Hyclone (Logan, UT). Human Oncostatin M 
(OSM) (Peprotech, Rocky Hill, NJ), interleukin-6 (IL-6), and leukemia inhibitory factor 
(LIF) (R & D Systems, Minneapolis, MN) were added at 25 ng/ml. 
Western Blot Analysis 
For whole cell lysates, 5 x 104 cells were seeded into 24-well plates (Thermo 
Fischer Scientific, Rockford, IL) unless otherwise stated. At the end of the experiment, 
plates were rinsed with ice-cold PBS, then placed on ice with 125 µl of RIPA buffer 
(Thermo Fischer Scientific) supplemented with 1:100 dilution of Sigma Protease 
Inhibitor Cocktail and 1 µl/ml phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis, 
MO) for 15 minutes, mixing every 5 minutes. Plates were scraped and the contents 
transferred to an eppendorf tube. Tubes were then centrifuged at 14,000 rpm for 20 
minutes. 
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For conditioned media, 2 x 105 cells were plated in a T25 flask containing RPMI 
media with 10% FBS. After 24 h, cells were treated with cytokines for 6 days. After 5 
days of cytokine treatment, media was replaced with serum-free RPMI along with fresh 
cytokines. Conditioned media was collected after 24 h. Floating cells were removed by 
centrifugation and media was concentrated using an Amicon Ultra-4 Centrifugal Filter 
with a 10K membrane (Millipore, Billerica, MA).   
Lysates were run on a 10% SDS-PAGE gel and transferred to a nitrocellulose 
membrane. Immunoblot analysis was performed using primary antibodies for human 
cathepsin D (1:500) (Calbiochem), JNK2 (1:500) (R & D Systems), β-actin (1:2000), 
phospho-STAT3 (Tyr705; 1:1000), STAT3 (1:500), or JNK1 (1: 500) (Cell Signaling, 
Beverly, MA). Secondary antibodies were HRP-conjugated donkey anti-rabbit or goat 
anti-mouse (1:5000-10,000) (Jackson Immuno Research Labs, West Grove, PA). 
Conditioned media was run as described above except for as a loading control the 
membrane was incubated in Ponceau S stain (0.1% (w/v) in 5% (v/v) acetic acid) for 1 
hour and then destained using distilled water before immunoblot analysis.   
RNA Interference and Chemical Inhibitors 
Gene knockdown of STAT3, JNK1, or JNK2-specific ON-TARGET plus siRNA 
or ON-TARGET plus non-targeting siRNA (Dharmacon, Lafayette, CO) was conducted 
using Hyperfect reagent (Qiagen, Valencia, CA) at a final concentration of 20 nM for 24 
hours before OSM stimulation. Seventy-two hours after the addition of OSM, cells were 
harvested for immunoblotting analysis. Gene knockdown of CTSD was conducted using 
2.5 x 105 cells in a 6-well plate (Thermo Fischer Scientific). A CTSD-specific Silencer 
Select siRNA (Applied Biosystems, Foster City, CA) was added using Hyperfect reagent 
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at a final concentration of 25 nM. After 24 hours, the media was replaced, and then 24 
hours later, media was replaced with serum-free media containing OSM. 72 hours after 
the addition of OSM, cells were processed for a Matrigel invasion assay, as described 
below. At the same time, media was removed and condensed, and cells were harvested as 
described above for immunoblotting.  
Inhibitors of the NA+/H+ exchanger (25 µM) (EIPA; Santa Cruz Biotechnology), 
MEK1/2 (5 µM) (U0126; Cell Signaling), PI3K (10 µM) (LY294002), p38 MAPK (10 
µM) (SB203580), Stat3 (5 µM) (Stat3 peptide inhibitor) or JNK (10 µM) (JNK inhibitor 
II; all from Calbiochem) were added on day 4 of cytokine treatment for conditioned 
media and replaced with the serum-free media and cytokines on day 5. For 
immunofluorescence, inhibitors were added on day 3 of cytokine treatment.  
Immunofluorescence Staining and Microscopy 
2.5 x 105 cells were plated onto glass coverslips (Thermo Fisher Scientific). After 
24 hours, cells were treated with or without OSM for 5 days. After experimental 
treatment, cells were rinsed once with PBS and then fixed in ice-cold methanol for 20 
minutes. Cells were then rinsed 3x with PBS and permeabilized in 0.1% Triton X-100/1X 
PBS for 10 minutes. Cells were then blocked in PBSAT (1X PBS/1% BSA/0.5%Triton 
X-100) for 30 minutes and then incubated in PBSAT containing the primary antibodies 
specific for human cathepsin D (1:200), LAMP1 (1:200; Millipore, Temecula, CA), 
and/or actin (1:400; Cell Signaling) overnight. Cells were then washed 3× in PBS and 
incubated with PBSAT containing goat anti-mouse Alexa Flour 488 (1:1000) and donkey 
anti-rabbit Alexa Flour 546 (1:500; Molecular Probes, Invitrogen, Carlsbad, CA) 
secondary antibodies for 2 h. Cells were then washed 3× in PBS and mounted using 
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Prolong Gold DAPI (Molecular Probes). Stains were visualized and confocal microscopy 
images were taken using a Zeiss LSM 510 Meta system combined with the Zeiss 
Axiovert Observer Z1 inverted microscope and ZEN 2009 imaging software (Carl Zeiss, 
Inc., Thornwood, NY).  
Invasion Assay 
The invasion assay was conducted as described previously 46 with the following 
modifications. A total of 2.5 x 10 4 cells from CTSD or non-target siRNA treated cells 
were plated with or without OSM in the upper chamber of the Matrigel-coated invasion 
chambers (BD Biosciences, Bedford, MA) in serum-free media, while media containing 
10% FBS was added to the bottom chamber as a chemoattractant and cells were allowed 
to invade for 22 hours. Invasion chambers were fixed in methanol and stained using 
crystal violet. Data are presented as previously described 21.  
Activity Assay 
Conditioned media was collected as described above. Active cathepsin D was 
then detected via a fluorescent cathepsin D (CTSD) activity assay (Anaspec, Fremont, 
CA). The assay was run according to the manufacturer’s protocol. To summarize, 2 x 105 
cells were plated in a T25 flask containing RPMI media with 10% FBS. After 24 h, cells 
were treated with cytokines for 6 days. After 5 days of cytokine treatment, media was 
replaced with serum-free RPMI along with fresh cytokines. Conditioned media was 
collected after 24 h. Floating cells were removed by centrifugation and media was 
concentrated using an Amicon Ultra-4 Centrifugal Filter with a 10K membrane 
(Millipore, Billerica, MA).  CTSD activity was then measured using a Mca/FRET 
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peptide, in which the FRET peptide is a cleavage site for CTSD. The fluorescence of Mca 
is quenched until the peptide is cleaved and measured as at excitation/emission of 
330nm/390nm. For data analysis, the relative fluorescent units (RFU) measured after 60 
minutes versus concentration of a serially diluted Mca standard were plotted. The amount 
of Mca produced by active CTSD from each experimental sample was determined from 
the standard.  
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RESULTS 
OSM Increases the Expression and Secretion of CTSD  
Cathepsin D (CTSD) has been found to be overexpressed in several neoplastic 
tissues 87 and carcinoma cells88 and can be induced by estrogen and other growth factors 
in breast cancer cells 78. CTSD is synthesized as a prepro-enzyme and after removal of 
the signal peptide, the 52 kDa proCTSD is targeted to the lysosomes89. The cleavage of 
the N-terminus results in a 48 kDa intermediate enzyme and further cleavage yields the 
active form composed of heavy (34 kDa) and light (14 kDa) chains associated by non-
covalent bonds 90–92.  
We have previously shown that OSM induces the secretion of CTSD from T47D 
human breast cancer cells, but it was not known if OSM-induced the expression of 
CTSD. To determine if OSM regulates CTSD expression, we treated MCF7 and T47D 
luminal epithelial-like/ER+ human breast cancer cells for 24, 48, and 72 hours with 25 
ng/ml of OSM. OSM induced a time-dependent induction of protein expression of all 
cellular isoforms of CTSD (Fig. 1). OSM treatment in MCF7 human breast cancer cells 
induced a greater increase in CTSD protein levels as early as 24 hours (Fig. 1A; left 
panel). T47D human breast cancer cells also induced CTSD protein levels, but 
differences in induction by OSM were not identified until 48 hours (Fig. 1A; right panel). 
To see if other IL-6 inflammatory cytokines also regulate CTSD expression, we treated 
MCF7 and T47D cells with IL-6 and leukemia inhibitory factor (LIF) for 72 hours. In 
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MCF7 cells, we observed a dramatic increase in CTSD protein expression with OSM 
treatment compared to IL-6 and LIF treatment (Fig. 1B; left panel). This trend was also 
seen in T47D cells (Fig. 1B; right panel). This indicates that OSM strongly promotes 
protein expression of CTSD and that OSM is a more potent inducer than other IL-6 
family cytokines.  
The secretion of CTSD from the cell appears to play a role in the progression of 
many cancers. The secreted forms of CTSD include the pro-form (52 kDa) and the 
mature form (heavy chain 34 kDa; light chain 14 kDa). Pro-CTSD acts as a mitogen for 
cancer and stromal cells 93,94, while the mature, active CTSD can directly modulate the 
ECM 49 or activate a proteolytic cascade in which other proteases modulate the ECM 
69,70
. Immunoblot analysis was performed using 10 µg of concentrated conditioned media 
collected from MCF7 and T47D human breast cancer cells treated with or without OSM, 
IL-6, or LIF (25 ng/ml) for 6 days. As seen in Fig. 1C, OSM-induced secretion of pro-
CTSD (52 kDa) and mature CTSD (34 kDa) in both MCF7 and T47D human breast 
cancer cell lines. The secretion of CTSD by OSM was greater than that of the control, IL-
6, or LIF treatments. Ponceau staining of the immunoblot confirmed equal loading of 
secreted protein (Fig. 1C; bottom panel). This indicates that OSM enhances the secretion 
of both the pro and active forms of CTSD to a greater extent than other IL-6 family 
cytokines.  
STAT3 and JNK2 Pathways Are Required for OSM-Induced CTSD Expression 
To identify the signaling pathway(s) necessary for the induction of CTSD 
expression by OSM in human breast cancer cells, we selectively inhibited the JAK/STAT 
pathway using a siRNA to STAT3 or the JNK pathway using JNK1 and JNK2 siRNAs 
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during cytokine treatment in MCF7 and T47D cells. In both the MCF7 and T47D cells, 
inhibition of STAT3 expression knocked down the induction of CTSD by OSM (Fig. 2A) 
while inhibition of JNK1expression did not affect OSM-induced CTSD expression (Fig. 
2B). Inhibition of JNK2 also reduced the induction of CTSD by OSM in both cell lines 
(Fig. 2C). It is interesting to note that although STAT3 and JNK2 knockdown blocked 
OSM-induced CTSD expression, basal levels remained and active CTSD (34 kDa) was 
present at high levels even though proCTSD (52 kDa) expression was inhibited, 
especially in the T47D cells (Fig 2 A-C; right panels).  This could imply that OSM 
regulates the transcription of new CTSD protein and not the processing of CTSD from 
the pro to active forms. In addition, inhibition using inhibitors of PI3K (LY294002), 
MEK1/2 (U0126), and p38 MAPK (SB203580) had no effect on OSM-induced CTSD 
expression (data not shown). Thus, activation of STAT3 and JNK2 appear to be 
necessary for the transcriptional regulation of CTSD by OSM.  
OSM Induces Trafficking of CTSD-Containing Lysosomes to Cellular Protrusions 
A hallmark of OSM-stimulated MCF7 or T47D human breast cancer cells in vitro 
is a loss in cobblestone epithelial morphology, leading to an increased migration and 
invasive potential 26–28. To determine if the formation of cellular protrusions induced by 
OSM treatment was accompanied by a change in the intracellular distribution of 
lysosomes, T47D cells were treated for 5 days before staining for the lysosomal marker, 
lysosome-associated membrane protein-1 (LAMP-1) and the cytoskeletal filament, actin 
(Fig. 3A). Figure 3A (right panel) shows that with OSM treatment, LAMP-1 positive 
vesicles (red) undergo anterograde trafficking toward the cell periphery. The figure also 
shows that OSM induces cytoskeletal rearrangement of actin (green), resulting in 
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increased cellular protrusions, similar to pseudopodia observed by others 95,96. Lysosomal 
trafficking to the cellular protrusions was observed.  Thus, morphological changes 
induced by OSM occur with anterograde lysosomal trafficking.  
To determine if the lysosomes contained CTSD, cells were co-stained to detect 
LAMP-1 (red) and CTSD (green) after 5 day treatment with OSM (Fig. 3B). Co-
localization is seen by the yellow vesicles in both the absence and presence of OSM (Fig. 
3B; right panels). The OSM treatment shows not only co-localization, but also 
anterograde trafficking of lysosomes containing CTSD to cellular protrusions with a high 
concentration of co-localized vesicles at the end of the protrusions (Fig. 3B; lower 
panels).  Lysosomal cathepsins have been shown to be important in invasion when 
trafficking is altered; therefore, this could an important mechanism in the increased 
secretion of cathepsins and increased invasive potential seen with OSM treatment.  
Moreover, increased activity of Na+/H+ exchangers (NHE) have been shown to 
play a role in lysosome trafficking 97,98 and NHE activity has been shown to be related to 
invadopodia-like structures 96,99 that degrade the ECM 100. To determine if OSM-induced 
cellular protrusions and lysosomal trafficking require NHE activity, cells were treated 
with 25 µM of the NHE inhibitor, EIPA (5-[N-ethyl-N-isopropyl]-amiloride) with or 
without OSM. EIPA was able to prevent OSM-induced anterograde lysosomal trafficking 
and decreased the secretion of CTSD by OSM (Fig. 3C). These data suggest that the 
NHE activity drives OSM-induced lysosomal trafficking and CTSD secretion from 
human breast cancer cells.  
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PI3K and p38 MAPK Pathways Are Required for OSM-Induced Lysosomal 
Trafficking 
To determine which pathway(s) are important for OSM-induced anterograde 
lysosomal trafficking, pathway specific inhibitors were used to block OSM signaling in 
T47D human breast cancer cells.  PI3K inhibition with LY294002 and p38 MAPK 
inhibition with SB203580 almost completely reversed anterograde lysosomal trafficking 
containing CTSD to cellular protrusions (Fig. 4; panels 2-3). However, inhibition of 
MEK with U0126, STAT3 with STAT3 inhibitor peptide, or JNKs 1, 2 and 3 with JNK 
inhibitor II did not alter lysosomal trafficking (Fig. 4; panels 4-6). This suggests that both 
PI3K and p38 MAPK pathways play a major role in OSM-induced lysosomal trafficking. 
Furthermore, these results imply that the signaling pathway for OSM-induced lysosomal 
trafficking is different than the pathway for OSM-induced CTSD expression. 
Enzymatically Active CTSD and Upregulation of CTSD Is Important for OSM-
Induced Invasion 
Altered localization and secretion of lysosomal cathepsins have been implicated 
in the localized proteolysis of the ECM and increased cell invasion 57,83,84,95. PI3K and 
p38 MAPK inhibition not only block lysosomal trafficking, but also the secretion of 
CTSD in T47D human breast cancer cells. Figure 5A shows that the secretion of both the 
pro and active forms of CTSD also decreased with PI3K (LY294002) and p38 MAPK 
(SB203580) inhibition, suggesting a role of lysosomal trafficking in OSM-induced CTSD 
secretion.  
To determine if the increased secretion of CTSD by OSM (Fig. 1C, Fig 5A) had a 
physiological consequence, the activity of the secreted CTSD was measured using a 
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fluorescent activity assay with a CTSD specific substrate. OSM treatment induced a two-
fold increase in the amount of active CTSD in the media (Fig. 5B). We also found that 
PI3K (LY294002) and p38 MAPK (SB203580) inhibitors blocked the OSM induced 
CTSD activity (Fig. 5B). This shows a correlation between the trafficking of lysosomes 
and the amount of active CTSD secreted from the cell.  
Next, to confirm the role of CTSD in OSM-induced invasion, RNAi-mediated 
silencing of CTSD in T47D cells was performed resulting in a decrease of OSM-induced 
CTSD expression (Fig. 5C; right panel). Cells were pretreated for 3 days with or without 
OSM, plated onto a Matrigel chamber, and allowed to invade for 22 hours. OSM 
treatment induced invasion of control siRNA T47D human breast cancer cells through a 
Matrigel chamber. OSM treated T47D cells with reduced CTSD induction had invasion 
levels similar to non-treated, control siRNA T47D cells (Fig. 5C; left panel). This data 
shows that knockdown of CTSD prevented the increased invasive potential, suggesting 
that CTSD plays an important role in OSM-induced invasion. 
16 
 
DISCUSSION 
Tumor growth and invasion can be regulated by many factors in the tumor 
microenvironment. The presence of IL-6 family cytokines have been suggested to 
contribute to tumor progression since it has been shown that chronic inflammation 
promotes tumorigenesis 6,101,102. While OSM has an anti-proliferative effect on many 
tumor types, it appears to play a role in tumor invasion and metastasis. Here we report a 
novel role for OSM signaling in breast cancer. When activated, OSM pathways induce 
the expression of CTSD and anterograde trafficking of lysosomes containing CTSD, 
resulting in an increase in CTSD secretion and invasion. OSM-induced CTSD expression 
depends on STAT3 and JNK2 pathways, while OSM-induced lysosomal and CTSD 
trafficking depends on NHE activity and the PI3K and p38 MAPK pathways. OSM 
induces the secretion of physiologically active CTSD, which also requires the PI3K and 
p38 pathways and may play a role in OSM-induced invasion since invasion was inhibited 
with CTSD knockdown. These data suggest that OSM signaling controls lysosomal 
distribution in tumor cells and that invasion may depend on lysosomal distribution and 
secretion of CTSD.  
In tumor progression, proteolytic enzymes have important functions and are often 
abnormally expressed or secreted 69.These proteases mediate the degradation of the ECM, 
increasing tumor cell invasion to a secondary site. CTSD is a lysosomal protease found to 
be overexpressed and hypersecreted in breast cancer 78,80,103,104. Studies have shown that 
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CTSD is important for invasion, migration, metastasis, and angiogenesis 61,82–85,95. Here 
we show that OSM is a potent inducer of CTSD expression and secretion in MCF7 and 
T47D human breast cancer cell lines and this increase in expression and secretion are 
greater than IL-6 and LIF (Fig. 1A-C). Our data show that the protease CTSD may 
contribute to the increase in breast cancer cell invasion, migration, metastasis, and 
angiogenesis by OSM that we and others have seen.  
Next, signaling pathways of OSM-induced CTSD expression were investigated. 
STAT3 is the classical signaling pathway for OSM and other IL-6 family cytokines. 
OSM has also been shown to be a strong activator of the JNK MAPK pathway 
specifically through the gp130/OSMRβ complex 44. We found that JNK1 has no effect on 
CTSD induction, but that OSM signals through STAT3 and JNK2 induce CTSD 
expression (Fig. 2). The JNK protein kinases are activated by MKK4 or MKK7 in 
response to cytokines or cell stress, and studies have shown their importance in 
malignancy 105. However, JNK2 may not directly promote CTSD expression. MKK4 106, 
the upstream activator or JNK2, and JNK2 107 both regulate the serine 727 
phosphorylation of STAT3. Phosphorylation of this site is required for maximal STAT3 
transcriptional activation 108,109. Thus, JNK2 may be required for maximal transcription 
of cathepsin D induced by OSM via STAT3.  
Several studies have focused on OSM-induced EMT changes in cell morphology 
22,24,25
, but our data shows another important and novel implication of the morphological 
changes induced by OSM. We show that OSM promotes cellular protrusions containing 
lysosomes and CTSD that have undergone anterograde trafficking (Fig. 4B). Others have 
shown that cellular protrusions containing lysosomes or CTSD were induced by cellular 
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transformation 57,84,110, HGF treatment 59, or acidic extracellular pH 95,98. Additionally, Tu 
et al. have shown that lysosomal trafficking to podosomes in SRC-transformed 
fibroblasts resulted in ECM degradation due to protease secretion 111. Since OSM induces 
the secretion of lysosomal proteases, OSM-induced lysosomal trafficking is likely to be 
critical for the increased invasive potential with OSM treatment. More work will need to 
be completed to identify whether lysosomal phagocytosis or exocytosis occurs in OSM-
induced trafficking. We see large vesicles co-stained with LAMP-1 and CTSD that 
undergo anterograde trafficking with OSM (Fig. 3b). These could represent degradation 
of the ECM via phagocytosis of ECM53,54, which would mean CTSD would be actively 
degrading the ECM within the acidic vesicles. However, we do see an increase in 
secretion of CTSD with OSM treatment. This suggests induction of lysosomal exocytosis 
60,61
, especially because our cells were not cultured on an artificial ECM, and thus it 
would be unlikely that the large vesicles contain phagocytic material.  
Lysosomal proteases that undergo exocytosis still need an acidic environment for 
maximal enzymatic activity. Increased Na+/H+ exchanger isoform 1 (NHE1) activity 
decreases the pericellular pH. NHE1 activity results in cytoskeletal reorganization and 
formation of cellular protrusions at the leading edge 97 thought to represent invadopodia 
and lamellipodia 97,99 in which NHE1 becomes localized 96. NHE1 activation may be a 
key event in oncogenesis112 as the decrease in pericellular pH creates a favorable 
environment for many proteases, such as lysosomal cathepsins, that play a role in tumor 
cell migration and invasion due to degradation of the ECM at the invadopodia-like 
structures 100. Since the NHE inhibitor, EIPA, reversed the anterograde lysosomal 
trafficking in cells treated with OSM (Fig. 3C), we show that lysosomal trafficking is 
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mediated through the activity of NHEs. Our 2D model supports a link between OSM and 
NHE activity, which to our knowledge has never been shown. Based on these data, we 
hypothesize that OSM increases NHE1 activity to promote cellular protrusions and 
decrease pericellular pH, which result in lysosomal trafficking, the subsequent secretion 
and activation of lysosomal proteases, and cancer cell invasion. This would support the 
role of lysosomal exocytosis instead of phagocytosis. EIPA inhibits several NHE 
isoforms; thus, more work will need to be done to verify that the NHE1 is the most 
important isoform in OSM-induced lysosomal trafficking as seen by others. In addition, 
future studies will need to be done to determine if using EIPA to block NHE activity not 
only blocks the movement of lysosomes but also decreases OSM-induced invasive 
potential. The use of 3D models will help to show whether the increase in NHE activity 
and the movement of lysosomes to the periphery induced by OSM participate in the 
direct degradation of the ECM.  
We also saw that inhibitors of the PI3K (Fig. 4; panel 2) and p38 MAPK (Fig. 4; 
panel 3) pathways reversed the lysosomal trafficking induced by OSM. Others have 
shown that trafficking of lysosomes induced by HGF and acidic extraceullular pH is 
mediated through the PI3K pathway 59,98 and can induce cytoskeletal changes 24,43. While 
others have shown the p38 MAPK to be important in cytoskeletal changes 113–115. 
Cardone et al. 97 summarize the role of both PI3K and p38 in regulating NHE1 activity. 
At the pseudopodia distal tip, p38 regulates NHE1 via the PKA–RHOA–ROCK1–p38 
signaling cascade. This process is also mediated by PI3K 116. In normal cells, p38 has 
also been shown to directly phosphorylate NHE1, which could indicate a disregulated 
mechanism in cancer cells 117. Our data indicate that PI3K and p38 pathways activated by 
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OSM might drive NHE1 activity, leading to anterograde lysosomal trafficking. However, 
more work needs to be done to elucidate the roles of PKA, RHOA and ROCK1 in the 
signaling cascade.  
While reports have been conflicting about the roles of precursor versus active 
CTSD in the extracellular milieu, previous studies have shown that an increase in active 
CTSD is a useful indicator of poor outcome in node positive breast cancer patients 118and 
that mature CTSD in patient serum was a valuable marker since it was only found in 
breast cancer patients with metastatic disease 74. We saw a two-fold increase in active 
CTSD secretion induced by OSM (Fig. 5B) in breast cancer cell lines supporting the role 
of enzymatically active CTSD in the direct degradation of the ECM 119–123 and its role in 
the proteolytic cascade 69–72 leading to an increased rate of metastases. Moreover, we 
showed that OSM-induced CTSD plays a role in the increased invasion seen with OSM 
(Fig. 5C). These data support the role of lysosomal exocytosis since OSM induces the 
secretion of active CTSD due to lysosomal trafficking that depends on NHE activity. 
A proposed model summarizing OSM signaling in breast cancer is illustrated in 
Figure 6. The first label shows that OSM induces CTSD expression through activation of 
the STAT3 and JNK2 pathways. Second, OSM signaling through PI3K and p38 MAPK 
induces lysosomal trafficking to cellular protrusions that exhibit altered actin 
organization. Third, OSM regulates NHE activity, which induces lysosomal trafficking. 
PI3K and p38MAPK activation by OSM may mediate the increase in NHE signaling by 
OSM.  
In conclusion, this study demonstrates for the first time that OSM promotes 
CTSD expression and secretion via lysosomal trafficking. We show a novel role for OSM 
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in lysosomal trafficking that is mediated through OSM-induced NHE1 activity and 
possible link to invadopodia-like structures. Based on this study, we suggest OSM could 
be a viable target in the early stages of breast cancer cell metastasis.  
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Figure 1. OSM induces expression and secretion of cathepsin D from human 
breast cancer cells in vitro. A) Time dependent induction of intracellular CTSD protein 
by OSM, and B) induction of CTSD protein by IL-6 family cytokines in MCF7 and T47D 
cells. Cells were treated for 72 hours with 25 ng/ml of the indicated cytokine.  C) 
Secreted CTSD levels (as measured by Western blot analysis) were higher in OSM 
treated MCF7 and T47D than other IL-6 family cytokines. Cells were treated for 6 days 
with 25 ng/ml of the indicated cytokine.  
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Figure 2. STAT3 and JNK2 signaling regulate cathepsin D expression from 
human breast cancer cells in vitro. CTSD protein levels after A) STAT3 inhibition by 
transfection of STAT3 siRNA, B) JNK1 siRNA, and C) JNK2 siRNA 24h before OSM 
treatment in MCF7 and T47D cells. Cells were harvested after 72h treatment with or 
without 25 ng/ml of OSM and analyzed by Western blot analysis.  
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Figure 3. OSM induces changes in cell morphology and anterograde lysosomal 
trafficking requires NHE activity. A) Representative merged IF images depicting the 
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morphological changes of actin (green) and trafficking of lysosomes (red) before and 
after 5d treatment with OSM in T47D cells. DAPI stained nuclei appear blue. B) LAMP1 
(red; left panels) and cathepsin D (green; middle panels) colocalize (yellow; right panels) 
in the absence and presence of OSM. Shown also are nuclei (blue). Vesicles traffic to the 
cell periphery in OSM treated cells (bottom panels). C) Representative merged IF images 
of EIPA, a sodium-proton exchangers (NHE) inhibitor, treatment on day 3 of 5d OSM 
treatment; lysosomes (red), cathepsin D (green), and nuclei (blue). Secreted CTSD levels 
(Western blot) also decreased with EIPA treatment even in the presence of OSM. 
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Figure 4. Trafficking of CTSD within the lysosomes is dependent on PI3K and 
p38 MAPK pathways. Representative merged IF images of signaling inhibitor treatment 
added on day 3 of 5d OSM treatment. LAMP1 (red) and cathepsin D (green) colocalize 
(yellow) in the absence and presence of OSM. Shown also are nuclei (blue).Vesicle 
trafficking to the cell periphery is blocked with the PI3K (LY294002) and the p38 MAPK 
(SB203580) inhibitors.  
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Figure 5. OSM-induced CTSD is active and important for OSM-promoted 
invasive potential. T47D cells were treated for 6 days with OSM. PI3K (LY294002) and 
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p38 MAPK (SB203580) inhibitors were added on day 4 of cytokine treatment. A) 
Secreted levels of both proCTSD (52 kDa) and active CTSD (34 kDa) protein levels (as 
measured by Western blot analysis) decrease with inhibitor treatment  B) The amount of 
active CTSD secreted into the culture media was determined using an activity assay. C) 
T47D cells were pre-treated with control or CTSD siRNA, in the absence or presence of 
OSM. Cells were then seeded onto Matrigel chambers and allowed to invade for 22h in 
the presence or absence of OSM.  
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Figure 6 Overview of OSM signaling regulating CTSD expression and 
lysosome trafficking. 1) OSM activates STAT3 and JNK2 to induce the expression of 
CTSD after 24-48 hours. 2) OSM signaling through PI3K and p38 MAPK induces 
lysosomal trafficking to cellular protrusions with altered actin organization. 3) NHE 
activity induced by OSM induces lysosomal trafficking and may be mediated via PI3K 
and p38.   
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